Post-Translational Modifications in Multiple Myeloma: Mechanisms of Drug Resistance and Therapeutic Opportunities
Biomolecules · 2025
DOI: 10.3390/biom15050702 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biomolecules, 2025. Verfasst von Shuoyang Hu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology, School of Basic Medical Sciences, Xinjiang Medical University, Urumqi 830011, China. Hauptthemen laut MEDLINE: Multiple Myeloma, Protein Processing, Post-Translational, Drug Resistance, Neoplasm, Antineoplastic Agents. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 199 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Xinjiang Uygur Autonomous Region, Xinjiang Medical University National Young Talent Cultivation Program.
Abstract (Originalsprache)
Multiple myeloma (MM) remains an incurable hematologic malignancy due to the inevitable development of drug resistance, particularly in relapsed or refractory cases. Post-translational modifications (PTMs), including phosphorylation, ubiquitination, acetylation, and glycosylation, play pivotal roles in regulating protein function, stability, and interactions, thereby influencing MM pathogenesis and therapeutic resistance. This review comprehensively explores the mechanisms by which dysregulated PTMs contribute to drug resistance in MM, focusing on their impact on key signaling pathways, metabolic reprogramming, and the tumor microenvironment. We highlight how PTMs modulate drug uptake, alter drug targets, and regulate cell survival signals, ultimately promoting resistance to PIs, IMiDs, and other therapeutic agents. Furthermore, we discuss emerging therapeutic strategies targeting PTM-related pathways, which offer promising avenues for overcoming resistance to treatment. By integrating preclinical and clinical insights, this review underscores the potential of PTM-targeted therapies to enhance treatment efficacy and improve patient outcomes in MM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Immunology, School of Basic Medical Sciences, Xinjiang Medical University, Urumqi 830011, China.
- Xinjiang Key Laboratory of Molecular Biology for Endemic Diseases, Xinjiang Medical University, Urumqi 830011, China.
ORCID-Profile: Yasen Maimaitiyiming
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Xinjiang Uygur Autonomous Region
- Xinjiang Medical University National Young Talent Cultivation Program
- State Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia Fund
- Undergraduate Innovation Training Program of Xinjiang Medical University
Zitieren
APA
Hu, S., Xu, J., Cui, W., Jin, H., Wang, X., & Maimaitiyiming, Y. (2025). Post-Translational Modifications in Multiple Myeloma: Mechanisms of Drug Resistance and Therapeutic Opportunities. Biomolecules. https://doi.org/10.3390/biom15050702
Vancouver
Hu S, Xu J, Cui W, Jin H, Wang X, Maimaitiyiming Y. Post-Translational Modifications in Multiple Myeloma: Mechanisms of Drug Resistance and Therapeutic Opportunities. Biomolecules. 2025. doi:10.3390/biom15050702
BibTeX
@article{Hu2025,
author = {Hu, Shuoyang and Xu, Jirun and Cui, Weiyan and Jin, Haoran and Wang, Xiaoyu and Maimaitiyiming, Yasen},
title = {Post-Translational Modifications in Multiple Myeloma: Mechanisms of Drug Resistance and Therapeutic Opportunities},
journal = {Biomolecules},
year = {2025},
doi = {10.3390/biom15050702}
}
EUVIMED